|

Lutetium Lu 177 Dotatate Clinical Trials

8 actively recruiting trials across 6 locations

Also known as: 177 Lu-DOTA-TATE, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, 437608-50-9, Lutathera, Lutetium (177Lu) Oxodotreotide, 177 Lu-DOTA-TATE, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera, Lutetium (177Lu) Oxodotreotide, Lutetium Lu 177 DOTA(0)-Tyr(3)-Octreotate, Lutetium Lu 177 Dotatate, 177 Lu-DOTA-Tyr3-Octreotate, 177Lu-DOTA0-Tyr3-Octreotate +8 more

Pipeline

Phase 1: 2Phase 2: 5Phase 4: 1

Top Sponsors

  • National Cancer Institute (NCI)4
  • Weill Medical College of Cornell University1
  • Vanderbilt-Ingram Cancer Center1
  • Mayo Clinic1
  • Emory University1

Indications

  • Cancer8
  • Unresectable Digestive System Neuroendocrine Tumor G22
  • Unresectable Digestive System Neuroendocrine Tumor G12
  • Unresectable Digestive System Neuroendocrine Neoplasm1
  • Digestive System Neuroendocrine Tumor1

Birmingham, Alabama2 trials

Duarte, California2 trials

Atlanta, Georgia1 trial

Iowa City, Iowa1 trial

Rochester, Minnesota1 trial

Nashville, Tennessee1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.